Across TCGA pan-cancer cohorts, C16orf87 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of C16orf87’s most consistent transcriptional readouts.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where C16orf87 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types C16orf87 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.
LSCC and CCRCC are the cancer types where C16orf87 tumor–normal differential expression is most reproducible.